Accure Therapeutics is a Barcelona neuroscience R&D company advancing ACT-02, a novel Prolyl Endopeptidase (PREP) inhibitor intended as a disease‑modifying therapy for Parkinson’s disease. The ACT-02 program is at an advanced preclinical stage with comprehensive positive efficacy data in Parkinson’s in vivo models and a GLP toxicology and safety pharmacology data set. Accure reports neuroprotective effects, reduced α-synuclein aggregation, decreased neuroinflammation, improved mitochondrial function, and motor/cognitive benefits in Thy1‑aSyn mouse studies. The company plans to complete the preclinical activities required for an IND filing and to start a phase I IND study targeted for 2026. Recent non-dilutive funding includes grants to support IND-enabling work and translational iPSC‑based studies to inform patient selection for future precision‑medicine strategies. Management states these steps are intended to advance ACT-02 toward clinical development in Parkinson’s disease. Accure Therapeutics is an R&D-focused company formed in 2020 to develop a portfolio of CNS drug candidates. The company launched with three programs (ACT-01, ACT-02 and ACT-03): ACT-01 is positioned to enter Phase 2 and ACT-02 and ACT-03 are in preclinical studies. Its initial pipeline targets four CNS indications: optic neuritis, multiple sclerosis, Parkinson’s disease and epilepsy. Initial assets were sourced from Spanish R&D companies Bionure and Iproteos and from academic neurobiology research centers. Accure follows a lean pharma R&D model that integrates existing assets, experienced personnel, programs and high-value investors to create patient and shareholder value. The company intends to expand the current portfolio into additional innovative R&D programs for CNS indications.

Total raised

$10M

Funding rounds

2

Latest round

Grant

Latest activity

Apr 2025